ESTRELLA IMMUNOPHARMA INC

Estrella Immunopharma’s stock surged 37.5% as investors eye its dual‑target CAR‑T pipeline, offering a potential buying window below the 200‑day average.

Estrella Immunopharma surges 37.5% as investors rally behind its CD19/CD22 T‑cell therapy pipeline—stock now $0.55 with strong buying momentum.